Overexpressed FOXM1 collaborates with MMB to increase WEE1 inhibitor sensitivity in NSCLC

被引:0
|
作者
Tan, Jian [1 ]
Ma, Jingbo [1 ]
Zhang, Weiqiang [1 ]
Zhao, Jing [1 ]
Liu, Keqiang [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Thorac Surg, 5 Nanmencang, Beijing 100000, Peoples R China
关键词
Forkhead box M1 (FOXM1); MYB-MuvB complex (MMB); Wee1-like protein kinase (WEE1); non-small cell lung cancer (NSCLC); CELL-CYCLE; B-MYB; CANCER; PROLIFERATION; EXPRESSION; KINASE; MUVB;
D O I
10.21037/jtd-23-750
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Non-small cell lung cancer (NSCLC) is a common lung tumor with high mortality. The complex formed by MYB-MuvB complex (MMB) and forkhead box M1 (FOXM1) (MMB-FOXM1) plays a vital role in cell cycle progression to affect the progression of diseases. The role of the FOXM1-MMB complex in Wee1-like protein kinase (WEE1) inhibitor sensitivity in NSCLC keeps unclear. Methods: The reverse transcription quantitative polymerase chain reaction (RT-qPCR) was performed to measure the mRNA levels of FOXM1, LIN54, Replication Protein A (RPA), gammaH2AX (gamma H2AX) and Cyclin B (CCNB). The western blot was performed to examine the corresponding protein expressions. The Cell Counting Kit-8 (CCK-8) assay was performed to test cell survival. Result: It was demonstrated that after AZD-1775 treatment, the decrease in cell survival mediated by FOXM1 overexpression (P<0.001) could be reversed by LIN54 knockdown (P<0.01) and that cell survival in the control group did not differ obviously from that in the pcDNA3.1-FOXM1+siLIN54 group, indicating that the FOXM1-MMB complex was necessary for WEE1 inhibitor sensitivity. Moreover, the mRNA and protein expression levels of RPA and gamma H2AX were increased after AZD-1775 treatment and FOXM1 overexpression (P<0.01), suggesting that FOXM1 upregulation enhanced DNA replication stress and DNA damage. Finally, we found that the increases in the mRNA and protein expression levels of CCNB mediated by FOXM1 (P<0.01) could be rescued by silencing LIN54 (P<0.001) and that CCNB expression in the control group did not differ obviously from that in the pcDNA3.1-FOXM1+siLIN54 group. These findings revealed that the FOXM1-MMB complex activated G2/M checkpoints. In our work, it was discovered that FOXM1 overexpression increased DNA replication stress, which increased DNA replication and pressure on the WEE1 checkpoint. On the other hand, FOXM1 can enhance CCNB expression, increase the threshold content of the CCNB/CDK1 complex, facilitate mitosis, and promote WEE1 dephosphorylation. Under these two conditions, sensitivity to the WEE1 inhibitor AZD-1775 is increased, which leads to the accumulation of DNA damage and drives the activation of apoptosis. Conclusions: Overexpressed FOXM1 collaborates with MMB to increase WEE1 inhibitor sensitivity in NSCLC. This discovery might highlight the regulatory function of FOXM1/MMB in the treatment of NSCLC patients.
引用
收藏
页码:3350 / 3358
页数:9
相关论文
共 50 条
  • [1] FOXM1 drives HPV plus HNSCC sensitivity to WEE1 inhibition
    Diab, Ahmed
    Gem, Hakan
    Swanger, Jherek
    Kim, Hee Yeon
    Smith, Kaleb
    Zou, Grace
    Raju, Sharat
    Kao, Michael
    Fitzgibbon, Matthew
    Loeb, Keith R.
    Rodriguez, Cristina P.
    Mendez, Eduardo
    Galloway, Denise A.
    Sidorova, Julia M.
    Clurman, Bruce E.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (45) : 28287 - 28296
  • [2] Targeting FoxM1 in ATL cells: application of FoxM1 inhibitor, thiostrepton
    Nakano, Kazumi
    Yamamoto, Naoka
    Tanabe, Aki
    Nakakido, Makoto
    Utsunomiya, Atae
    Tsumoto, Kohei
    Watanabe, Toshiki
    Uchimaru, Kaoru
    CANCER SCIENCE, 2018, 109 : 1238 - 1238
  • [3] WEE1 Inhibitor: Clinical Development
    Anthony Kong
    Hisham Mehanna
    Current Oncology Reports, 2021, 23
  • [4] WEE1 Inhibitor: Clinical Development
    Kong, Anthony
    Mehanna, Hisham
    CURRENT ONCOLOGY REPORTS, 2021, 23 (09)
  • [5] MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity
    Branigan, Timothy B.
    Kozono, David
    Schade, Amy E.
    Deraska, Peter
    Rivas, Hembly G.
    Sambel, Larissa
    Reavis, Hunter D.
    Shapiro, Geoffrey, I
    D'Andrea, Alan D.
    DeCaprio, James A.
    CELL REPORTS, 2021, 34 (09):
  • [6] WEE1 kinase inhibitor shows promise
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (10) : 593 - 593
  • [7] Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
    Seo, Hye-Rim
    Nam, Ah-Rong
    Bang, Ju-Hee
    Oh, Kyoung-Seok
    Kim, Jae-Min
    Yoon, Jeesun
    Kim, Tae-Yong
    Oh, Do-Youn
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 541 - 553
  • [8] Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
    Nam, Ah-Rong
    Jin, Mei-Hua
    Bang, Ju-Hee
    Oh, Kyoung-Seok
    Seo, Hye-Rim
    Oh, Do-Youn
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2020, 52 (03): : 945 - 956
  • [9] WEE1 kinase inhibitor shows promise
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2019, 16 : 593 - 593
  • [10] Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
    Caiola, Elisa
    Frapolli, Roberta
    Tomanelli, Michele
    Valerio, Rossana
    Iezzi, Alice
    Garassino, Marina C.
    Broggini, Massimo
    Marabese, Mirko
    SCIENTIFIC REPORTS, 2018, 8